AI has designed candidate drugs for antibiotic-resistant infections and genetic diseases. But efforts to incorporate AI into the design of lipid nanoparticles (LNPs), the revolutionary delivery ...

The proposed partnership would deploy Claude to private equity portfolio companies using a Palantir-style consulting model, ...

Therapeutic developers are increasingly rebuilding their workflows around AI to bring drugs to patients faster.